Dataset Information

Genetic sequencing analysis of the A307 subgroup of ABO blood group.

ABSTRACT: The aim of this study was to investigate the serology and gene sequence characteristics of the A307 subgroup of ABO blood group. Monoclonal anti-A and anti-B antibodies were used to detect the ABO antigens of a proband whose positive blood type was not consistent with the negative blood type of ABO blood group. Meanwhile, standard A-, B-, and O-negative typing cells were used to test for ABO antibodies in the serum. Additionally, polymerase chain reaction with sequence-specific primer (PCR-SSP) was used to confirm the genotype, and subsequently, exons 6 and 7 of the ABO gene were detected by gene sequencing. Samples from the wife and daughters of the proband were also used for serological and genetic testing. Red blood cells of the proband showed weak agglutination reaction with anti-A antibody, while anti-B antibody was detected in the serum. Moreover, PCR-SSP detected A307 and O02 alleles, while gene sequencing revealed mutation of c.745C>T in exon 7, which produced a polypeptide chain p.R249W. Furthermore, the A307 gene of the proband was not inherited by his daughters. A mutation (c.745 C>T) in exon 7 of the ABO blood group gene resulted in low activity of ?-1, 3-N-acetyl-galactosaminyl transferase, producing A3 phenotype.

SUBMITTER: Huang Y

PROVIDER: S-EPMC4537950 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genetic sequencing analysis of the A307 subgroup of ABO blood group.

Huang Ying Y Lin Jiajin J Zhu Suiyong S

International journal of clinical and experimental medicine 20150615 6

The aim of this study was to investigate the serology and gene sequence characteristics of the A307 subgroup of ABO blood group. Monoclonal anti-A and anti-B antibodies were used to detect the ABO antigens of a proband whose positive blood type was not consistent with the negative blood type of ABO blood group. Meanwhile, standard A-, B-, and O-negative typing cells were used to test for ABO antibodies in the serum. Additionally, polymerase chain reaction with sequence-specific primer (PCR-SSP) ...[more]

PMID: 26309629

Similar Datasets

Project description:IntroductionABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information.ObjectiveHere, we report a next generation sequencing (NGS)-based assay for predicting the prenatal ABO blood group.Materials and methodsA total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-free DNA was PCR-amplified using 2 primer sets followed by NGS. NGS data were analyzed by 2 different methods, FASTQ analysis and a grep search, to ensure robust results. The fetal ABO prediction was compared with the known serological infant ABO type, which was available for 19 samples.ResultsThere was concordance for 19 of 19 predictable samples where the phenotype information was available and when the analysis was done by the 2 methods. For immunized pregnant women (n = 20), the risk of HDFN was predicted for 12 fetuses, and no risk was predicted for 7 fetuses; one result of the clinical samples was indeterminable. Cloning and sequencing revealed a novel variant harboring the same single nucleotide variations as ABO*O.01.24 with an additional c.220C>T substitution. An additional indeterminable result was found among the 6 test samples and was caused by maternal heterozygosity. The 2 indeterminable samples demonstrated limitations to the assay due to hybrid ABO genes or maternal heterozygosity.ConclusionsWe pioneered an NGS-based fetal ABO prediction assay based on a cell-free DNA analysis from maternal plasma and demonstrated its application in a small number of samples. Based on the calculations of variant frequencies and ABO*O.01/ABO*O.02 heterozygote frequency, we estimate that we can assign a reliable fetal ABO type in approximately 95% of the forthcoming clinical samples of type O pregnant women. Despite the vast genetic variations underlying the ABO blood groups, many variants are rare, and prenatal ABO prediction is possible and adds valuable early information for the prevention of ABO HDFN.

Dataset Information

Genetic sequencing analysis of the A307 subgroup of ABO blood group.

Publications

Genetic sequencing analysis of the A307 subgroup of ABO blood group.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets